Related Experiment Video
Updated: Oct 8, 2025
08:17
Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa
Published on: September 27, 2018
8.6K
Axonics Sacral Neuromodulation System for Treating Refractory Overactive Bladder: A NICE Medical Technologies
Ruth Louise Poole1, Megan Dale2, Helen Morgan3
1Cedar, Cardiff and Vale University Health Board, Cardiff, UK. Ruth.Poole@wales.nhs.uk.
Applied Health Economics and Health Policy
|December 29, 2021
Summary
The Axonics rechargeable sacral neuromodulation (SNM) system offers a promising solution for refractory overactive bladder (OAB). This innovative technology may reduce symptoms and potentially save costs compared to non-rechargeable systems.
Area of Science:
- Urology
- Medical Technology
- Health Economics
Background:
- Refractory overactive bladder (OAB) significantly impacts quality of life.
- Conservative treatments and medications are often insufficient for OAB management.
- Existing sacral neuromodulation (SNM) systems typically use non-rechargeable batteries.
Purpose of the Study:
- To evaluate the evidence for the Axonics rechargeable SNM system for refractory OAB.
- To assess the potential benefits and cost-effectiveness of this new technology.
- To inform adoption decisions within the UK National Health Service (NHS).
Main Methods:
- Review of evidence considered by the UK National Institute of Health and Care Excellence (NICE).
- Analysis of two observational studies on symptom improvement post-implantation.
- Economic modeling based on battery life estimates and comparative cost analysis.
Main Results:
- Observational data suggest symptom improvement in urge urinary incontinence and urinary frequency.
- No direct comparative peer-reviewed evidence exists between rechargeable and non-rechargeable SNM systems.
- Economic modeling indicates potential cost savings of £6025 per person over 15 years compared to non-rechargeable systems.
Conclusions:
- The Axonics rechargeable SNM system is supported as a viable option for refractory OAB when other treatments fail.
- Potential cost savings are significant, contingent on the claimed 15-year battery life.
- Adoption aligns with existing NICE guidelines for OAB management.
Related Concept Videos
01:30Urinary Tract Calculi III: Medical Management
48
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
48
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
448
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
448
01:23Urinary Bladder
1.8K
The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
1.8K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
350
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
350